[Antiphospholipid syndrome: possible pathogenic mechanisms of thrombosis].
Velasco
F
F
Servicio de Hematología, Hospital Universitario Reina Sofía, Córdoba.
López-Pedrera
C
C
Torres
A
A
Cuadrado
M J
MJ
Dobado-Berrios
P M
PM
D000925:Anticoagulants / Q000627:therapeutic use; D016824:Antigens, Human Platelet / Q000276:immunology; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000150:complications*; D004730:Endothelium, Vascular / Q000378:metabolism; D011464:Epoprostenol / Q000378:metabolism; D005342:Fibrinolysis; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D010974:Platelet Aggregation; D011486:Protein C / Q000502:physiology; D012008:Recurrence; D013921:Thrombocytopenia / Q000139:chemically induced / Q000276:immunology; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000097:blood / Q000209:etiology*
D000925:Anticoagulants; D016824:Antigens, Human Platelet; D016682:Lupus Coagulation Inhibitor; D011486:Protein C; D011464:Epoprostenol
Síndrome antifosfolípido (SAF): posibles mecanismos patogénicos de trombosis.